DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xpht8z/liquid_biopsy) has announced the addition of the "Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets" report to their offering.
This report provides an in-depth study of the liquid biopsy diagnostics industry. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region. The market sizes are given for the years 2014, 2015 and 2020.
The structure of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from 2013 to the present. Industry subsectors analyzed include NGS instruments, droplet digital PCR, target enrichment and amplification, single cell DNA polymerase, noninvasive prenatal screening and general liquid biopsy.
The market for liquid biopsy diagnostics is analyzed in depth. It covers commercialized diagnostic tests. The pure research field is excluded. The market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region, including North America, Europe, Asia-Pacific and the rest of the world. Applications in this report include PCR-based, NGS-based, others (microarray, cytometry, Sanger sequencing, fluorescent in situ hybridization (FISH), and immunohistochemistry (IHC)).
Biomarker types in this report include cfDNA, CTC and EV. Therapeutic areas in this report include cancer, NIPT and transplant. Market data covers the years 2014, 2015 and 2020. More than 85 companies in the liquid biopsy industry are profiled in this report. A summary of the main industry acquisitions and strategic alliances from 2013 through 2015 is provided, including key alliance trends.
Highlights:
- The global liquid biopsy market should reach nearly $4.5 billion in 2020 from $1.6 billion in 2015, registering a CAGR of 22.3% for the period of 2015-2020.
- The cancer application market will increase at a CAGR of 36.2% over the forecast period to grow from $414.5 million in 2015 to $1.9 billion in 2020.
- The non-cancer application market as a segment reached $1.2 billion in 2015 and should reach $2.5 billion by 2020 increasing at a CAGR of 15.7%.
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Overview
Chapter 4: Technologies
Chapter 5: Liquid Biopsy Initiatives
Chapter 6: Liquid Biopsy Applications
Chapter 7: Liquid Biopsy Industry
Chapter 8: Acquisitions And Strategic Alliances
Chapter 9: Markets
Chapter 10: Patents
Chapter 11: Company Profiles - Partial List
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Cytotrack Aps
- Danaher Corp.
- Diagnologix Llc
- Dna Electronics Ltd.
- Epic Sciences
- Exosome Diagnostics Inc.
- Fluidigm Corp.
- Foundation Medicine
- Fluxion Biosciences Inc.
- Gatc Biotech Ag
- Ge Healthcare
- Genomic Health Inc.
- Gigagen Inc.
- Good Start Genetics Inc.
- Merck Kgaa
- Myriad Genetics Inc.
- Natera Inc.
- Neogenomics Inc.
- New England Biolabs
- New Oncology Ag
- Nugen Technologies Inc.
- Qiagen Nv
- Raindance Technologies Inc.
- Rarecells Sas
- Rarecyte Inc.
- Resolution Bioscience Inc.
- Roche Holding AG
- Sequenom Inc.
- Silicon Biosystems
- Sphere Fluidics Ltd.
- Strand Life Sciences
- Stratec Biomedical Ag
- Sygnis AG
For more information visit http://www.researchandmarkets.com/research/xpht8z/liquid_biopsy
